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Prediction of Pathological complete response to Neoadjuvant chemotherapy for primary breast cancer 
comparing interim ultrasound, shear wave elastography and MRI 
 
Advances in Knowledge 
 
SWE stiffness after 3 cycles of NACT is strongly associated with pCR after 6 cycles.  
Use of a 50kPa cut-off is more useful than using the percentage reduction in stiffness. 
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Abstract 
Background:  Prediction of Pathological complete response (pCR) of primary breast cancer to NACT may 
influence planned surgical approaches in the breast and axilla.  The aim of this project is to assess the 
value of interim shearwave elastography (SWE),ultrasound (US) and MRI after 3 cycles in predicting pCR.  
Methods: 64 patients receiving NACT had baseline and interim US, SWE and MRI examinations.  Mean 
stiffness at SWE, US and MRI diameter were measured at both time points. We compared four 
parameters with pCR status: a). Interim mean stiffness ≤ or >  50 kPa ; b). Percentage stiffness reduction; 
c). Percentage US diameter reduction and d). Interim MRI response using RECIST criteria.  The Chi square 
test was used to assess significance.   
Results: Interim stiffness of ≤ or >50kPa gave the best prediction of pCR with pCR was seen in 10 of 
14(71%) women who had an interim stiffness of ≤50kPa, compared to 7 of 50(14%) of women who had 
an interim stiffness of >50kPa, (p<0.0001) (sensitivity 59%, specificity 91%, positive predictive value 71%, 
negative predictive value 86% and diagnostic accuracy 83% ). Percentage reduction in stiffness was the 
next best parameter (sensitivity 59% specificity 85%, p<0.0004) followed by reduction in MRI diameter 
of >30% ( sensitivity 50% and specificity 79%, p=0.03) and  % reduction in US diameter (sensitivity 47%, 
specificity 81%, p=0.03).  Similar results were obtained from ROC analysis.    
Conclusion: SWE stiffness after 3 cycles of NACT is strongly associated with pCR after 6 cycles.  
Introduction 
Pathological complete response (pCR) is increasingly common after neoadjuvant chemotherapy (NACT) 
for primary invasive breast cancer.  Early prediction of pCR may influence planned surgical approaches in 
the both the breast and axilla.  Knowledge of response before the end of chemotherapy is helpful when 
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planning complex autologous breast reconstructions especially if pre-reconstruction sentinel node 
biopsy is contemplated.  
Interim assessment of response is usually carried out using MRI which has been shown to be superior to 
mammography and clinical examination in this clinical setting (1).  In many series MRI is also superior to 
ultrasound (US) (1,2).  Standard MRI assessment uses RECIST criteria which is based on changes in 
unidimensional measurements.  However, both volumetric, functional and texture based MRI 
assessment have been shown to be superior at interim prediction, particularly in luminal and hybrid 
subgroups (3-6).  MRI has the disadvantages of being expensive, time consuming and in many centres 
there are availability issues.  
Shearwave elastography (SWE) is an ultrasound imaging method which allows reproducible 
quantification of lesional and peri-lesional stiffness and it has been shown to aid benign/malignant 
differentiation of breast masses (7,8).  It has also been shown to be an independent predictor of nodal 
metastasis and response to NACT at baseline (9,10).  SWE is fast to perform and interpret.  
One previous study has assessed the value of SWE in predicting pCR at the end of NACT (11).  The 
authors found that SWE performed similarly to MRI and better than US. Two previous studies have 
looked at interm assessment with SWE.  On assessed interim prediction with SWE and strain 
elastography to response (12) while the other compared interim SWE alone to response (13)  Neither of 
these studies compared the SWE findings with those of MRI or grey scale US, the modalities routinely 
used in this clinical setting.  We therefore hypothesised that SWE may be useful in interim assessment of 
response in women undergoing NACT. The aim of this project was to assess the value of interim SWE 
compared to US and MRI after 3 cycles in predicting pCR after 6 cycles of NACT. 
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Materials and methods 
Sixty four patients with breast cancer receiving NACT were recruited into an ethically approved study 
which included baseline and interim US, SWE and MRI examinations.  No patients were excluded after 
initial inclusion. Interim imaging examinations were performed after 3 cycles of chemotherapy, with 
patients proceeding to 6 cycles in total. All US scans were performed by one of five breast radiologists or 
one advanced radiography practitioner trained to perform and interpret breast ultrasound using an 
Aixplorer® ultrasound system (SuperSonic Imagine, Aix en Provence, France). These practitioners had 
between 7 and 22 years of breast ultrasound experience and had at least 12 months experience of 
performing SWE of solid breast lesions.  
Four SWE images in two orthogonal planes were obtained. The ROI utilized in all cases was 2mm in 
diameter.  Maximum diameter was obtained from the US images.  Mean stiffness in kPa was taken as 
the average of the values taken from four SWE images taken in two orthogonal planes.  Imaging data 
was acquired prospectively, so without knowledge of the final pathological outcome. If the lesion was 
not seen on US then the US diameter was taken as 1mm while SWE readings in the region of the 
previous abnormality were taken, this was identified by looking at the body mark on the previous US 
and viewing the pre-treatment MRI.  Percentage reductions in tumour diameter and mean stiffness 
were calculated.   Cut off values for percentage reduction in diameter and stiffness were chosen to give 
the same proportion of patients in the good response group as patients had a pCR at surgery.  The 
percentage  reduction in stiffness and US diameter were combined and assessed as a potential 
parameter. This was done by comparing the median values for US diameter and stiffness at baseline for 
the whole data set.  The median values for US diameter values in mm were 4.8 times smaller than the 
stiffness values in kPa.  Therefore the US diameter values were multiplied by 4.8 and then added to the 
stiffness measurement to give a combination value.  An absolute cut off value for interim SWE values of 
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50kPa was also applied as this is a cut off value established in the literature for the differentiation of 
benign and malignant masses (7,14).  
All MR examinations were performed on a 32-channel 3.0 Tesla (T) Siemens Magnetom Trio scanner 
(Erlangen, Germany) with a 7-channel open breast biopsy coil.  Patients were imaged in a head-first 
prone position.  Early post contrast T1 weighted sequences were used to obtain measurements of 
tumour on pre NACT and interim scans and RECIST criteria used to assign patient to assessment 
categories.    
pCR was classified as an absence of any invasive cancer cells in the tumour bed at surgical resection 
after 6 cycles of NACT and an absence of nodal metastases at axillary surgery.   However all women with 
a pCR in this study also had no DCIS in the tumour bed at resection.   
Sensitivity, specificity and diagnostic accuracy were calculated for each modality and modality 
combination, and the  chi-square test was used to assess the statistical significance of differences.  
Means and associated standard deviations were calculated for lesion sizes and stiffness before 
treatment and at interim.    Receiver operator characteristic (ROC) curves were produced and the area 
under the curve (AUC) determined using Medcalc software.  A pairwise statistical comparison of the ROC 
curves was also performed.   
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Results 
Sixty four patients constituted the study group.  The mean age was 52yrs (range 25-79yrs).  Twenty-five 
patients had triple negative tumours, 21 had HER2 +ve cancers and 18 had luminal cancers.  The first 3 
cycles of chemotherapy in all patients consisted of 5-fluorouracil, epirubicin and cyclophosphamide 
(FEC).   The mean pre NACT stiffness was 127.4 kPa (range 55-289, SD =54) and the mean pre-treatment 
US size was 27mm (range 8-45, SD 9).    pCR occurred in 17 of 64 (27%) women (Figure 1) while 47 
patients had residual disease (Figure 2).  At interim scanning a residual US visible mass was seen in 62 of 
64 (97%) women.  Of the 2 women with no US mass on interim scanning, one had a focal area of 
residual stiffness.  Both of these patients had a pCR.   The mean interim stiffness was 90.3 kPa (range 17-
218, SD 55) and the mean interim US size was 21mm (range 1-43, SD 10). 
pCR was seen in 10 of 14(71%) women where masses had an interim stiffness value of <50kPa, 
compared to 7 of 50(14%) of women whose masses had an interim stiffness value of ≥50kPa, p<0.0001. 
Using this 50kPa cut off gave a sensitivity of 59%, specificity 91%, PPV 71%, NPV 86% and a diagnostic 
accuracy of 83% (Table 1).   Increasing or lowering this threshold did not improve overall performance.  
The cut off value for percentage reduction in stiffness giving the same proportion of patients (17/64, 
27%) as those showing a pCR was 50%.  The cut off value for percentage reduction in US dimeter giving 
the same proportion of patients (17/64, 27%) as those showing a pCR was 61%. The cut off value for 
percentage reduction in stiffness and US diameter combined and giving the same proportion of patients 
(27%) as those showing a pathological pCR was 114%.  The associations between pCR and changes in US 
and SWE parameters based on these cut-off values at interim scanning are shown in Table 1.  The 
diagnostic accuracy using percentage reduction in stiffness, percentage reduction in US diameter and a 
combination of percentage reduction of stiffness and US diameter were 78%, 72% and 75% respectively. 
The percentage reduction in stiffness and percentage reduction in US diameter gave statistically 
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significant results (p<0.0004 and p=0.03 respectively).  The combination of percentage reduction in 
stiffness and US diameter did not improve performance compared to that achieved by percentage 
reduction in stiffness alone (Table 1).   
Baseline and interim MRIs were available for 59 of 64 (92%) patients.  Using a >30% reduction in 
diameter as an indicator of response, the sensitivity, specificity and diagnostic accuracy of MRI were 
50%, 79% and 71% respectively.   The percentage reduction in MRI diameter and its association with pCR 
was statistical significant (p=0.03)(Table 1). 
ROC analysis gave the following AUC measurements for predicting pathological complete response at 
interim assessment; change in MRI diameter 0.68, percentage change in stiffness 0.82, stiffness value at 
interim 0.78, percentage change in US diameter 0.67 and percentage change in a combination of change 
in US diameter and reduction in stiffness 0.83.  The ROC curves are shown in Figures 3 to 7.   All these 
ROC curves shown on one graph are shown in Figure 8.  The only statistically significant difference in 
AOC measurements following a pairwise comparison was that between percentage change in US 
diameter and the combination of US diameter change and stiffness change (p=0.02). 
Images where different imaging modalities gave differing interim estimates of response are shown in 
Figures 9 and 10.  
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Discussion 
We have shown that interim SWE after 3 cycles of NACT using a simple threshold of 50 kPa for mean 
elasticity is strongly associated with the chance of a pCR after 6 cycles of NACT. This simple threshold 
assessment has a stronger association with pCR than estimating the percentage reduction in stiffness.  
Both these parameters appear to outperform greyscale US assessment using uni-dimensional diameter 
and MRI using RECIST criteria when analysis is performed using cut off values.   Analysis using ROC 
curves suggests that percentage change in stiffness and percentage change of a combination of US 
diameter change and stiffness change are the best parameters at interim scanning to predict pCR at the 
end of treatment. However assessed, the best parameters include SWE assessment.   
A common problem using greyscale US to assess tumour response to NACT is that many cancers when 
treated go from an ovoid shape to a flatter, plaque like appearance.  When this happens, the uni-
dimensional diameter can remain unchanged even if the tumour volume has reduced considerably.  This 
problem can be overcome by using volumetric assessments using a 3D probe.  One study has shown the 
use of a 3D probe to be helpful in this clinical setting (15).  However 3D probes only have a footprint of 
4cm so they are not able to measure the volume of large tumours.  Many tumours also cause 
considerable posterior shadowing which can obscure the posterior border of the tumour and so 
interfere with volumetric assessment. Another problem when using US is that even when a pathological 
complete response has been achieved a residual mass of fibrous tissue is seen, measured and assumed 
to be viable tumour. One advantage of using SWE is that these residual fibrous masses with no residual 
cancer tend to be soft on SWE so assessment on SWE is less prone to errors of this nature.   SWE 
benefits from being easy to perform and that the results have good reproducibility with intra-class 
coefficient (ICCC) for quantitative measurements between scans taken by different observers being 0.85 
which is in the “near perfect” range if 4 images are taken in 2 planes . Stiffness measurements taken by 
different observers from the same scans have an ICCC of 0.99.  Qualitaitve ssessments of SWE images 
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(not performed in this study) are less reproducible (7, 14,16).  Performance of SWE on breast masses 
have a few limitations. Lesions very deep in the breast can be difficult to assess and patients with 
breathing difficulties can also be impossible to scan accurately.     
It is becoming more common to see pCR in breast cancer as NACT regimens become more effective, 
resulting in more women undergoing surgical resection of breast tissue even though no viable tumour is 
present (17).   In response to this, clinical study of the use of percutaneous sampling of the tumour bed 
using vacuum assisted biopsy devices becomes more attractive (18).  Before this can happen, imaging 
prediction of pCR has to improve.  It is becoming clear that pure anatomical assessment of the tumour 
bed is not fit for purpose and that functional assessment either using MRI or other modalities such as 
PET/CT or SWE  offer superior prediction (3,5,19). It is also becoming clear that different 
immunophenotypes of breast cancer have different rates and patterns of response to NACT and that 
this necessitates a tailored approach by the radiologist when assessing response to NACT (4).   
Response to NACT of the primary tumour is also important in guiding axillary surgery, as response in the 
axilla is closely correlated to response of metastatic disease in axillary lymph nodes.  In patients who 
have biopsy proven axillary disease but appear to have a pCR prior to surgery there is now some 
evidence to suggest the safety of a sentinel node biopsy rather than an axillary clearance, albeit with a 
higher false negative rate than previously accepted (20).  Thus correct and accurate assessment of 
response to NACT prior to surgery will influence both surgical options for the tumour bed and the axilla.  
This study has a number of limitations.  It comes from a single centre with a special research interest in 
SWE but as the technique is straightforward to perform we do not foresee difficulty in other centres 
replicating these results.  The number of patients in the study is modest so differences in performance 
according to immunophenotype have not been assessed.  It is possible that SWE may perform better in 
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certain immunophenotypes in this setting as this is certainly the case when using SWE to predict 
response at baseline and when using MRI to predict pCR at interim scanning (4,21).   
Two previous similarly sized recent studies have addressed the topic of assessing interim response of 
breast cancer to NACT using SWE.  Their finding are comparable to our study.  What is new in the 
current study is showing that SWE interim assessment is at least as accurate as grey scale US or MRI 
using RECIST criteria.  No studies have been performed assessing the value of SWE in assessing response 
after 1 or 2 cycles of NACT. It is therefore unclear how soon SWE could be used to assess response after 
the commencement of NACT.  A previous study has assessed the value of assessing response to NACT 
with SWE at the end of NACT.  They found that a threshold of 30kPa was useful in predicting response.  
They found this cut off value more predictive than other higher values.  They did not attempt to look at 
the value of percentage reduction in stiffness compared to baseline values (11).   
In conclusion, SWE shows promise as a method of interim prediction of response in women with breast 
cancer treated with NACT and could be used to inform surgical decision making.  
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Figure legends 
Figure 1.  Images showing baseline and interim US (a,b), SWE (c,d) and MRI (e,f) in a woman who 
achieved a pCR correctly predicted by all modalities 
Figure 2.  Images showing baseline and interim US (a,b), SWE (c,d) and MRI (e,f) in a woman who had 
residual invasive cancer correctly predicted by all modalities 
Figure 3.  ROC curve demonstrating the relationship between change in MRI diameter between baseline 
and interim scanning and pCR. The AOC is 0.68 (95% CI’s  0.54 to 0.79) 
Figure 4.  ROC curve demonstrating the relationship between percentage change in stiffness between 
baseline and interim scanning and pCR. The AOC is 0.82 (95% CI’s  0.70 to 0.90)  
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Figure 5.  ROC curve demonstrating the relationship between stiffness at interim scanning and pCR. The 
AOC is 0.77 (95% CI’s  0.65 to 0.87)  
Figure 6.  ROC curve demonstrating the relationship between percentage change in US diameter 
between baseline and interim scanning and pCR. The AOC is 0.67 (95% CI’s  0.54 to 0.78)  
Figure 7.  ROC curve demonstrating the relationship between percentage change in the combination of 
US diameter and stiffness between baseline and interim scanning and pCR. The AOC is 0.83 (95% CI’s  
0.71 to 0.91)  
Figure 8.  ROC curve demonstrating the relationship between the different parameters and pCR.     
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 pCR  (n)  No pCR (n) p-value sensitivity specificity Diagnostic 
accuracy 
Shearwave 
<50 kPa at 
interim 
10 4 <0.0002 59% 91% 83% 
Shearwave 
≥50 kPa at 
interim 
7 43 
Stiffness  
<52% of 
baseline 
10 6 <0.0004 59% 85% 78% 
Stiffness  
≥52% of 
baseline 
6 36 
US diameter  
<61% of 
baseline 
8 9 0.026 47% 81% 72% 
US diameter 
≥61% of 
baseline 
9 38 
Combination 
reduction 
<114% 
9 8 <0.004 53% 83% 75% 
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Combination 
reduction ≥ 
114% 
8 39 
MRI >30% 
reduction in 
diameter 
8 9 0.03 50% 79% 71% 
MRI< 30% 
reduction 
diameter 
8 34 
 
Table 1 
Associations between changes in US, SWE and MRI parameters at interim scanning and pCR at the end 
of NACT 
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